Chapter 53 Structural effects of oncogenic PI3Kα mutations.

Chapter 54 Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.

Chapter 60 From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development

Chapter 62 Faithfull Modeling of PTEN Loss Driven Diseases in the Mouse

Chapter 63 Comparing the Roles of the p110α and p110β Isoforms of PI3K in Signaling and Cancer

Chapter 64 New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)

Chapter 65 PI3K: from the bench to the clinic and back.

Chapter 66 AKT Signaling in Physiology and Disease

Chapter 67 Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Chapter 68 Oncogenic mutations of PIK3CA in human cancers.

Chapter 71 PI3K as a Target for Therapy in Haematological Malignancies

Chapter 80 Phosphatidylinositol 3-kinase: the oncoprotein.